Key Points
- Insider sale: Mike Mensinger sold 7,800 shares on January 2 at an average price of $29.61 for $230,958, trimming his position by 8.59% to 82,952 shares (≈$2.46M).
- Company performance: Beta Bionics has a market cap of $1.30B, trades near its recent highs (52‑week range $8.89–$32.71) and posted an earnings quarter that beat revenue and EPS estimates despite remaining unprofitable with large negative margins.
- Analyst sentiment: Multiple firms have raised price targets and reiterated buy ratings, leaving the stock with a consensus "Moderate Buy" rating and an average target of about $29.70.
Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) insider Mike Mensinger sold 7,800 shares of the firm's stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $29.61, for a total transaction of $230,958.00. Following the completion of the sale, the insider owned 82,952 shares in the company, valued at approximately $2,456,208.72. The trade was a 8.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Mike Mensinger also recently made the following trade(s):
- On Tuesday, December 2nd, Mike Mensinger sold 1,063 shares of Beta Bionics stock. The shares were sold at an average price of $29.34, for a total transaction of $31,188.42.
Beta Bionics Price Performance
Shares of Beta Bionics stock opened at $29.57 on Tuesday. The company has a market cap of $1.30 billion and a PE ratio of -6.77. The firm has a fifty day moving average price of $29.08 and a two-hundred day moving average price of $22.01. Beta Bionics, Inc. has a fifty-two week low of $8.89 and a fifty-two week high of $32.71.
Beta Bionics (NASDAQ:BBNX - Get Free Report) last announced its quarterly earnings data on Tuesday, October 28th. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.12. Beta Bionics had a negative net margin of 87.89% and a negative return on equity of 35.72%. The business had revenue of $27.25 million during the quarter, compared to analyst estimates of $23.92 million.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Invesco Ltd. acquired a new position in Beta Bionics in the first quarter worth $202,000. Nuveen LLC acquired a new position in shares of Beta Bionics during the first quarter valued at $209,000. MetLife Investment Management LLC acquired a new stake in Beta Bionics in the first quarter worth about $102,000. Corebridge Financial Inc. acquired a new position in Beta Bionics during the 1st quarter valued at about $79,000. Finally, Alyeska Investment Group L.P. bought a new position in shares of Beta Bionics in the 1st quarter worth $918,000.
Analyst Ratings Changes
A number of research firms have recently issued reports on BBNX. Stifel Nicolaus restated a "buy" rating and set a $31.00 price objective (up from $26.00) on shares of Beta Bionics in a research report on Wednesday, October 29th. Robert W. Baird set a $28.00 price target on shares of Beta Bionics in a research note on Tuesday, December 16th. Truist Financial increased their price objective on shares of Beta Bionics from $32.00 to $37.00 and gave the company a "buy" rating in a research note on Thursday, December 18th. The Goldman Sachs Group raised their price objective on shares of Beta Bionics from $26.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, October 29th. Finally, Piper Sandler reissued an "overweight" rating and issued a $32.00 target price (up previously from $26.00) on shares of Beta Bionics in a research note on Wednesday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $29.70.
Get Our Latest Stock Analysis on Beta Bionics
About Beta Bionics
(
Get Free Report)
Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company's flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.
At the core of Beta Bionics' offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
